Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04999839 · ClinicalTrials.gov registry record · Phase 2
Study of NDI-034858 in Participants With Moderate to Severe Plaque Psoriasis
A Phase 2 study, sponsored by Takeda.
- Completed
- Registry status
- Phase 2
- Development phase
- 259
- Enrollment target
NCT04999839 is a Phase 2 study that has completed, run by Takeda. The registered enrollment target is 259 participants.
The verdict
NCT04999839, a Phase 2 study, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 259 participants
- Enrollment target
Study Summary
This is a Phase 2b, randomized, multicenter, double-blind, placebo-controlled, multiple-dose study designed to evaluate the efficacy, safety, and tolerability of NDI-034858 in participants with moderate to severe plaque psoriasis. This study will also evaluate the plasma concentrations of NDI-034858 and explore the immune response to NDI-034858 in participants with moderate to severe plaque psoriasis.
Interventions
- OTHER Placebo
- DRUG NDI-034858 study drug
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 259 participants |
| Start Date | 2021-08-11 |
| Est. Completion | 2022-09-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04999839
The ClinicalTrials.gov registry entry for NCT04999839 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 259 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04999839 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04999839 about?
NCT04999839 is a clinical study titled "Study of NDI-034858 in Participants With Moderate to Severe Plaque Psoriasis". This is a Phase 2b, randomized, multicenter, double-blind, placebo-controlled, multiple-dose study designed to evaluate the efficacy, safety, and tolerability of NDI-034858 in participants with moderate to severe plaque psoriasis. This study will also evaluate the plasma concentrations of NDI-034858...
What is the current status of trial NCT04999839?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 259 participants. The study started on 2021-08-11. Estimated completion is 2022-09-12.
What interventions are being tested in trial NCT04999839?
The interventions under investigation include: Placebo (OTHER), NDI-034858 study drug (DRUG).
Who is sponsoring clinical trial NCT04999839?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.